Filing Flows › Arcturus Therapeutics Holdings (ARCT) › R&D spending
Arcturus Therapeutics Holdings (ARCT) R&D spending by quarter
Arcturus Therapeutics Holdings' R&D spending was $17.0M in Q3 2026 (third quarter 2026), -3% from Q2 2026. Over the last 7 quarters it ranged from $17.0M (Q3 2026) to $34.9M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $17.0M | -3% | -27% |
| Q2 2026 | $17.5M | -19% | -41% |
| Q1 2026 | $21.5M | -12% | -38% |
| Q4 2025 | $24.5M | +5% | — |
| Q3 2025 | $23.3M | -21% | — |
| Q2 2025 | $29.6M | -15% | — |
| Q1 2025 | $34.9M | — | — |
Q3 2026 at a glance
Arcturus Therapeutics Holdings, Q3 2026: revenue $18.3M (+7% year over year), operating margin -50.2%, net loss $7.4M, operating cash flow −$6.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arcturus Therapeutics Holdings' R&D spending?
Arcturus Therapeutics Holdings' R&D spending was $17.0M in Q3 2026 (third quarter 2026), -3% from Q2 2026.
How has Arcturus Therapeutics Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $17.0M (Q3 2026) to $34.9M (Q1 2025).
Q3 2026 results → · How Arcturus Therapeutics Holdings makes money →